Tumor necrosis factor β and soluble APO-1/Fas independently predict progression to AIDS in HIV-seropositive patients

AIDS Research and Human Retroviruses

Volumn 14, Issue 10, 1998, Pages 835-843

  Medrano, Francisco J ^a   Leal, Manuel ^a   Arienti, Donatella ^b   Rey, Concepcion ^a   Zagliani, Arianna ^b   Torres, Yolanda ^a   Sanchez Quijano, Armando ^a   Lissen, Eduardo ^a   Clerici, Mario ^b,c  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC VALUE; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; SEROPREVALENCE; VIREMIA;

EID: 0032504086     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1998.14.835     Document Type: Article

References (70)

1. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, and Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (London) 1995;373:123-127.
2. Giorgi JV, Fahey JL, Smith DC, et al.: Early effects of HIV on CD4 lymphocytes in vivo. J Immunol 1987;138:3725-3730.
3. Miedema F, Petit AJ, Terpstra FG, et al.: Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men. HIV affects the immune system before CD4+ T helper cell depletion occurs. J Clin Invest 1988; 82:1908-1916.
4. Clerici M, Stocks NI, Zajac RA, Bosweli RN, Lucey DR, Via CS, and Shearer GM: Detection of three distinct pattern of T helper cell dysfunction in asymptomatic, HIV-seropositive patients. J Clin Invest 1989;84:1892-1899.
5. Gougeon ML, Olivier S, Garcia D, et al.: Mise en evidence d'un processus d'engagement vers la mort cellulaire par apoptose dans les lymphocytes de patients infecte par le VIH. CR Acad Sci Paris. Ser III Sc Vie 1991;312:529-540.
6. Amiesen JC and Capron A: Cell dysfunction and depletion in AIDS: The programmed cell death hypothesis. Immunol Today 1991;12:102-106.
7. Meyaard L, Otto SA, Jonker RR, Mijnster MJ, Keet RPM, and Miedema F: Programmed cell death of T cells in HIV infection. Science 1992;257:217-219.
8. Oyaizu N, McCloskey TW, Coronesi M, Chirmule N, Kalyanaraman VS, and Pahwa S: Accelerated apoptosis in PBMC from human immunodeficiency infected patients and in CD4 cross-linked PBMC from normal individuals. Blood 1993;82:3392-3400.
9. Gougeon ML, Garcia S, Heeney J, et al.: Programmed cell death in AIDS-related HIV and SIV infections. AIDS Res Hum Retroviruses 1993;9:553-560.
10. Cao Y, Qin L, Zhang L, et al.: Virologic and immunologic characterization of long-term survivors of HIV type 1 infection. N Engl J Med 1995;332:201-208.
11. Reid MJ, Goetz DW, Zajac RA, Houk RW, and Bosweli RN: The natural history of HIV infection in screened HIV positive US Air Force personnel: A preliminary report. J AIDS 1988;2:70-76.
12. Fahey JL, Taylor JMG, Detels R, et al.: The prognostic value of cellular and serologic markers in infection with HIV type 1. N Engl J Med 1990;322:166-172.
13. MacDonnel KB, Chmiel JS, Poggensee L, Wu S, and Phair JP: Predicting progression to AIDS. Combined usefulness of CD4 lymphocyte counts and p24 antigenemia. Am J Med 1990;89:706-712.
14. Lifson AR, Hessol NA, Buchbinder SP, et al.: Serum β2microglobulin and prediction of progression to AIDS in HIV infection. Lancet 1992;339:1436-1440.
15. Shafer RW and Merigan TC: New virologic tools for the design of clinical trials. J Infect Dis 1995;171:1325-1328.
16. Mellors JW, Kingsley LA, Rinaldo CR, et al.: Quantification of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995;122:573-579.
17. Katzenstein DA, Hammer SM, Hughes MD, et al.: The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996;335:1091-1098.
18. Koot M, Keet IPM, Vos AHV, et al.: Prognostic value of human immunodeficiency virus type 1 biological phenotype for rate of CD4 depletion and progression to AIDS. Ann Intern Med 1993; 118:681-688.
19. Schuitemaker H, Koot M, Koostra NA, et al.: Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: Progression of disease is associated with a shift from monocytotropic to T-cell tropic virus population. J Virol 1992;66:1354-1360.
20. Kozal MJ, Shafer RW, Winters MA, Katzenstein DA, Aguiniga E, Halpern J, and Merigan TC: HIV-1 syncytium-inducing phenotype, virus burden, codon 215 transcriptase mutation and CD4 cell decline in zidovudine-treated patients. J Acquir Immune Defic Syndr 1994;7:832-838.
21. Calderon E, Torres Y, Medrano FJ, Luque F, Larder B, Rey C, et al.: Emergence and clinical relevance of mutations associated with zidovudine resistance in asymptomatic HIV-1 infected patients. Eur J Clin M Infect Dis 1995;6:512-519.
22. Vykamam A, McKeating J, Meager A, and Beverley PC: Tumor necrosis factor (α, β) induced by HIV-1 in peripheral blood mononuclear cells potentiates virus replication. AIDS 1990; 4:21-27.
23. Mellors JW, Griffith BP, Ortis MA, Landry ML, and Ryan JL: Tumor necrosis factor-α/cachectin enhances human immunodeficiency virus type 1 replication in primary macrophages. J Infect Dis 1991;163:78-82.
24. Matsuyama T, Kobayashi N, and Yamamoto N: Cytokines and HIV infection: Is AIDS a tumor necrosis factor disease? AIDS 1991;5: 1405-1417.
25. Clerici M, Sarin A, Berzofsky JA, et al.: Antigen-stimulated CD4+ T cell death in HIV infection is selective for CD4+ T cells, regulated by cytokines and affected by lymphotoxin. AIDS 1996;10: 603-311.
26. Katsikis PD, Garcia-Ojeda ME, Wunderlich ES, et al.: Activation-induced peripheral blood T cell apoptosis is Fas independent in HIV-infected individuals. Int Immunol 1996;8:1311-1317.
27. Katsikis PD, Garcia-Ojeda ME, Torres-Roca JF, Greenwald DR, Herzenberg LA, and Herzenberg LA: HIV type 1 Tat protein enhances activation but not Fas (CD95)-induced peripheral blood T cell apoptosis in healthy individuals. Int Immunol 1997;9:835-841.
28. Krammer PH, Dhein J, Walczak J, et al.: The role of APO-1-mediated apoptosis in the immune system. Immunol Rev 1994;142: 175-191.
29. Katsikis PD, Wunderlich ES, Smith CA, Herzenberg LA, and Herzenberg LA. Fas antigen stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus infected individuals. J Exp Med 1995;181:2029-2036.
30. Estaquier J, Idziorek T, Zou W, et al.: T helper 1/T helper 2 cytokines and T cell death: Preventive effect of IL-12 on activation-induced and CD95 (Fas/Apo-1)-mediated apoptosis of CD4+ T cells from HIV-infected persons. J Exp Med 1995;182:1759-1767.
31. Silvestris F, Cafforio P, Frassanito MA, Tucci M, Romito A, Nagata S, and Dammacco F: Overexpression of Fas antigen on T cells in advanced HIV-1 infection: Differential ligation constantly induces apoptosis. AIDS 1996;10:131-141.
32. Sloan EM, Young NS, Kumar P, Weichold FF, Sato T, and Maciejewski JP: Role of Fas ligand and receptor in the mechanism of T cell depletion in acquired immunodeficiency syndrome: Effect on CD4+ lymphocyte depletion and human immunodeficiency virus replication. Blood 1997;8:1357-1363.
33. Knippling E, Debatin KM, Stricker K, et al.: Identification of soluble APO-1 in supematants of human B and T cell lines and increased serum levels in B and T cell leukemias. Blood 1995;85: 1562-1569.
34. Tanaka M, Suda T, Haze K, et al.: Fas ligand in human serum. Nature Med 1996;2:317-322.
35. Cheng J, Zhou T, Liu C, et al.: Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994; 263:1759-1762.
36. Dembic Z, Loetscher H, Gubler U, et al.: Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences. Cytokine 1990;2:231-237.
37. Loecher H, Pan YCE, Lahm HW, et al.: Molecular cloning and expression of the human 55 kD tumor necrosis factor receptor. Cell 1990;61:351-359.
38. Rimaniol AC, Boussin F, Herbelin A, Groote DD, Dormont D, Bach JF, et al.: Induction of soluble tumor necrosis factor receptor (sTNF-R75) release by HIV absorption on cultured human monocytes. Eur J Immunol 1994;24:2055-2060.
39. Aukrust P, Liabakk NB, Muller F, Lien E, Espevik T, and Froland SS: Serum levels of tumors necrosis factor-α (TNF-α) and soluble TNF receptors in human immunodeficiency virus type 1 infection. Correlation to clinical, immunological and virological parameters. J Infect Dis 1994;169:420-424.
40. Godfried MH, Van der Poll T, Weverling GJ, et al.: Soluble receptors for tumor necrosis factor as predictors of progression to AIDS in asymptomatic human immunodeficiency virus type 1 infection. J Infect Dis 1994;169:739-745.
41. Lahadervita J, Maury CPJ, Teppo AM, and Repo H: Elevated levels of circulating cachetin/tumors necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med 1988;85:289-291.
42. Luque F, Caruz A, Pineda JA, Torres Y, Larder B, and Leal M: Provirus load in untreated and zidovudine-treated human immunodeficiency virus type 1-infected patients. J Infect Dis 1994;169: 267-273.
43. Leal M, Torres Y, Medrano FJ, Calderon E, Key C, and Lissen E: Does early zidovudine treatment prevent the emergence of syncytium-inducing human immunodeficiency virus? J Infect Dis 1994;170:1041.
44. Torres Y, Medrano FJ, Rey C, Calderon E, Sanchez-Quijano, Lissen E, and Leal M: Cytokine network and HIV syncytium-inducing phenotype shift. AIDS 1996;10:1053-1055.
45. Leal M, Torres Y, Medrano FJ, Rey C, Caruz A, Sanchez-Quijano, and Lissen E: HIV-1 viremia changes in patients with and without syncytium-inducing phenotype treated with nucleoside analogues: A case control study. Eur J Clin Invest 1996;26:923-928.
46. Centers for Disease Control: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992;41(RR-17):1-19.
47. Larder BA, Kellan P, and Kemp SD: Zidovudine resistance predicted by direct detection of mutation in DNA from HIV-infected lymphocytes. AIDS 1991;5:137-144.
48. Koot M, Schellekens PTHA, Mulder JWH, et al.: HIV-1 biological phenotype in long-term infected individuals, evaluated with an MT-2 cocultivation assay. AIDS 1992;6:49-54.
49. Duh EJ, Maury WJ, Folk TM, Fauci AS, and Rabson AB: Tumor necrosis factor α activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-κB site long terminal repeat. Proc Natl Acad Sci USA 1989;86:5974-5978.
50. Terai C, Komblut RS, Pavia D, Richman DD, and Carson DA: Apoptosis as a mechanism of cell death in cultured T lymphoblasts acutely infected with HIV-1. J Clin Invest 1991;87:1710-1715.
51. Banda NK, Bernier J, Kurahara DK, et al.: Crosslinking CD4 by HIV gp120 primes T cells for activation-induced apoptosis. J Exp Med 1992;176;1099-2006.
52. Lewis DE, Ng Tang DS, Adu-Oppo GA, Shober W, and Rodgers JR: Anergy and apoptosis in CD8+ T cells from HIV-infected persons. J Immunol 1994;93:982-988.
53. Jaleco AC, Covas MJ, and Victorino RMM: Analysis of lymphocyte cell death and apoptosis in HIV-2 infected patients. Clin Exp Immunol 1994;98:185-189.
54. Clerici M, Sarin A, Coffman RL, et al: Type 1/type 2 cytokine modulation of T cell programmed cell death as a model for HIV pathogenesis. Proc Natl Acad Sci USA 1994;91:11811-11815.
55. Alderson MR, Tough TW, Davis-Smith T, et al: Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 1995;181:71-77.
56. Dhein J, Walczac H, Baumler C, Debatin K-M, and Krammer PH: Autocrine T cell suicide mediated by APO-1 (Fas/CD95). Nature (London) 1995;373:438-441.
57. Brunner T, Mogul R, LaFace D, et al.: Cell-autonomous Fas (CD95)/Fas ligand interaction-mediated activation-induced apoptosis in T cell-hybridoma. Nature (London) 1995;373: 441-444.
58. Ju S-T, Panka DJ, Cui H, et al.: Fas (CD95)/FasL interactions required for programmed cell death after T cell activation. Nature (London) 1995;373:444-448.
59. Estaquier J, Tanaka M, Suda T, Nagata S, Golstein P, and Ameisen JC: Fas-mediated apoptosis of CD4+ and CD8+ cells from human immuno-deficiency virus-infected persons: Differential in vitro preventive effect of cytokines and protease antagonists. Blood 1996;87:4959-4966.
60. Katsikis PD, Garcia-Ojeda ME, Torres-Roca JF, Tijoe IM, Smith CA, Herzenberg LA, and Herzenberg LA: Interleukin-1 beta converting enzyme-like protease involvement in Fas-induced and activation-induced peripheral blood T cell apoptosis in HIV infection. TNF-related apoptosis-induced ligand can mediate activation-induced T cell death in HIV infection. J Exp Med 1997;186: 1365-1372.
61. Badley AD, McElhinny JA, Leibson PJ, Lynch DH, Alderson MR, and Paya, CV: Upregulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytes. J Virol 1996;70:199-206.
62. Badley AD, Dockrell D, Simpson M, Schul R, Lynch DH, Leibson P, and Paya CV: Macrophage-dependent apoptosis of CD4+ T lymphocytes from HIV-infected individuals is mediated by FasL and tumor necrosis factor. J Exp Med 1997;185:55-64.
63. Oyazu N, Adachi Y, Hashimoto F, et al.: Monocytes express Fas ligand upon CD4 cross-linking and induce CD4+ T cell apoptosis: A possible mechanism of bystander cell death in HIV infection. J Immunol 1997;158:2456-2463.
64. Piazza C, Montani Gilardini MS, Moretti S, Cundari E, and Piccolella E: CD4+ T cells kill CD8+ T cells via Fas/Fas ligand-mediated apoptosis. J Immunol 1997;58:1503-1506.
65. Godfried MH, Van der Poll T, Jansen J, et al.: Soluble receptors for tumor necrosis factor: a putative marker of disease progression in HIV infection. AIDS 1993;7:33-36.
66. Aukrust P, Liabakk NB, Miller F, Lien E, Espevik T, and Froland SS: Serum levels of tumor necrosis factor-α (TNFα) and soluble TNF receptors in human immunodeficiency virus type 1 infection - correlations to clinical, immunologic, and virologic parameters. J Infect Dis 1994;169:420-424.
67. Bilello JA, Stellrecht K, Drusano GL, and Stein DS: Soluble tumor necrosis factor-α receptor type II (sTNFaRII) correlates with human immunodeficiency virus (HIV) RNA copy number in HIV-infected patients. J Infect Dis 1996;173:464-467.
68. Godfried MH, Van der Poll V, Mulder T, et al.: Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infection. J AIDS Hum Retrovirol 1995;10:531-539.
69. Frissen PHJ, Weverling GJ, Endert E, Jansen J, Sauerwein HP, and Lange JMA: Predictive value for survival of soluble tumor necrosis factor receptors p55 and p75 during zidovudine-containing treatment in symptomatic human immunodeficiency virus type 1 infection. J AIDS Hum Retrovirol 1996;12:482-488.
70. Dezude BJ: Pentoxifylline for the treatment of infection with human immunodeficiency virus. Clin Infect Dis 1994;18:285-287.